Clinical TrialJul 14, 2026, 09:02 AM
Ernexa Targets Q3 2026 IND for ERNA-101, Phase 1 Study in Q4 2026
AI Summary
Ernexa Therapeutics announced progress for its lead cell therapy candidate, ERNA-101, designed to treat advanced ovarian cancer. The company plans to submit an Investigational New Drug (IND) application in Q3 2026, with the first-in-human Phase 1 study anticipated to begin in Q4 2026. CEO Sanjeev Luther highlighted ERNA-101's potential to transform immunologically 'cold' tumors and discussed encouraging preclinical data, including complete tumor clearance and 100% long-term survival in ovarian cancer models.
Key Highlights
- IND submission for ERNA-101 planned for Q3 2026.
- First-in-human Phase 1 study for ERNA-101 anticipated in Q4 2026.
- ERNA-101 aims to transform immunologically 'cold' tumors in ovarian cancer.
- Preclinical data showed complete tumor clearance and 100% long-term survival in models.
- ERNA-101 utilizes a proprietary off-the-shelf iMSC platform.
Price Impact
More from ERNA